Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study | AMiner
Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 3. Patient responses to individual neoantigens at pre-treatment and post-treatment for patients who received mRNA-4157 monotherapy (A–C) or combination therapy (D–J) using ELISpot assay.
原文链接
分享
引用
